Dr. Toner is evaluating a novel adoptive T cell therapy for treatment of Peripheral T-Cell Lymphoma.
published research
Toner K, Bollard CM. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood. 2022.
Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanojevic M, Lazarski C, Shibli A, Bien SA, Maglo P, Hoq F, Schore R, Glenn M, Hu B, Hanley PJ, Ambinder R, Bollard CM. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2022.
Lazarski CA, Toner K, Keller MD, Luban N, Young PP, Bollard CM, Wagner SJ, Hanley PJ. Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures. Blood Transfus. 2021.
Raskin S, Van Pelt S, Toner K, Balakrishnan PB, Dave H, Bollard CM, Yvon E. Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Mol Ther Methods Clin Dev. 2021.
Toner K, Bollard CM, Dave H. T-cell therapies for T-cell lymphoma. Cytotherapy. 2019.